ストックスクリーナーアプリを入手
1.86
4.49%
0.08
Skye Bioscience Inc (SKYE) 最新ニュース
Skye Bioscience director Andrew Schwab sells $140,313 in stock By Investing.com - Investing.com India
Skye Bioscience director Andrew Schwab sells $140,313 in stock - Investing.com
5am Partners VII, LLC sells $140,313 of Skye Bioscience stock - Investing.com
Skye Bioscience (SKYE) insider funds sell 375,840 shares at $0.32–$0.41 - Stock Titan
Skye Bioscience (SKYE) 5AM funds sell at penny-level prices - Stock Titan
Skye Bioscience, Inc. Common Stock (NASDAQ: SKYE) Share Price, SKYE Stock News, SKYE Share Price & Updates - Kalkine
Form 8K Skye Bioscience Inc For: 19 August By Investing.com - Investing.com South Africa
Skye Bioscience flags Nasdaq noncompliance after stockholders’ equity falls to ($497,307) - Bitget
SKYE BIOSCIENCE INC(SKYE) Stock Options Chain | Quotes & News - Moomoo
Skye Bioscience Faces Nasdaq Compliance and Delisting Risk - TipRanks
Skye Bioscience receives Nasdaq notice for non-compliance with equity listing rule - Investing.com
Skye Bioscience Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Skye Bioscience (NASDAQ: SKYE) faces deadline to fix negative equity - Stock Titan
Skye Bioscience (SKYE) holder sells shares, funds Redx merger - Stock Titan
$SKYE BIOSCIENCE INC (SKYE.US)$ sure feels like it 😒 - Moomoo
Skye Bioscience Inc (SKYE) (Q2 2026) Earnings Call Highlights: S - GuruFocus
Skye Bioscience, Inc. (SKYE) Skye Bioscience, Inc.M&A CallSlideshow (NASDAQ:SKYE) 2026-08-16 - Seeking Alpha
Skye (SKYE) Drops -7.21% — Key Support at $0.47 2026-08-15Sign of Weakness - vinanet.vn
Skye drops obesity program, combines with Redx to form Fibrx - AllSci
Redx tries again at reverse merger, with Skye this time, as alternative route gains steam - Endpoints News
Skye Bioscience Q2 Loss Narrows Sharply on Lower R&D Spending - Minichart
SKYE: Merger creates Fibrx, a well-funded fibrosis company advancing RXC008 for Crohn's disease - TradingView
Skye Bioscience to Be Acquired by Redx Pharma in $264.5M Nasdaq-Listed Merger - Minichart
SKYE: Merger creates a well-funded fibrosis company advancing RXC008 for Crohn's disease, with phase II data due 2029 - TradingView
Form 8K Skye Bioscience Inc For: 14 August By Investing.com - Investing.com Nigeria
Skye Bioscience to acquire Redx Pharma in $125M deal By Investing.com - Investing.com Nigeria
Skye Bioscience to acquire Redx Pharma in $125M deal - Investing.com
Skye Bioscience to Acquire Redx; Secures $67.9M Financing and $22M Equity Line - TradingView
Skye Bioscience, Inc. 2026: Revenue $178.2K, EPS ($0.27) — 10-Q Summary - TradingView
Skye Bioscience (NASDAQ: SKYE) exits obesity trial, pursues Redx merger and $100M+ funding - Stock Titan
Skye Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings - marketscreener.com
Skye Bioscience (SKYE) Climbs 1.66% to $0.55: Consolidation Nears a Critical JunctureRating Change - Vinanet
SKYE Q1 2026 Earnings: Narrow EPS Miss Reflects Continued Clinical-Stage InvestmentEstimate Revision Count - vinanet.vn
SKYE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Skye Bioscience (SKYE) Jumps 10% as Shares Approach Key $0.55 ResistanceRounding Bottom - Vinanet
Skye Bioscience Inc (SKYE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Skye Bioscience Inc (SKYE) Stock News Today - TradingKey
SKYE Stockholders Have Opportunity to Lead Skye Bioscience, Inc - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, In - The National Law Review
SKYE Q2'26 Earnings: EPS estimate is (0.24) USD - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Skye Bioscien - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Skye Bioscience Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
Skye Bioscience2026 Funding Rounds & List of Investors - Tracxn
Skye Bioscience, Inc. Revenue Breakdown – NASDAQ:SKYE - TradingView
Skye Bioscience Inc. (SKYE) Q1 2026 Earnings: Clinical-Stage Losses Slightly Wider Than ConsensusEPS Surprise History - dars.gov.et
Skye Bioscience Inc (SKYE) Cash Flow - TradingKey
Skye Bioscience Inc (SKYE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
SKYE|Skye Bioscience Inc|Price:0.625|Chg%:-0.027 - TradingKey
Skye Bioscience, Inc. Revenue Breakdown – LSX:A3ES4X - TradingView
Skye Bioscience Inc (SKYE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Skye Bioscience Inc (SKYE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Skye Bioscience Market Sentiment - Benzinga España
SKYE Q1 2026 Earnings: Pre-Revenue Biotech Misses EPS Estimates, Stock DeclinesPre-Announcement Alert - vinanet.vn
TradingKey - TradingKey
Skye Bioscience Inc (SKYE) Institutional Confidence - TradingKey
Skye Bioscience Lawsuit: Company and CEO Move to Dismiss Claims - TipRanks
Skye Bioscience (SKYE) Edges Higher as Stock Holds Above Key Support at $0.63Wide Range Bar - dars.gov.et
Skye Bioscience (SKYE) Rallies 1.6% as Price Holds Key SupportFloat Adjusted Cap - vinanet.vn
Skye Bioscience (SKYE) Slides to $0.66 as Selling Pressure Mounts Near Support LevelsOpening Range Breakout - dars.gov.et
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):